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Abstract
There is an urgent need for an immunological correlate of protection against tuberculosis (TB) with which to evaluate
candidate TB vaccines in clinical trials. Development of a human challenge model of Mycobacterium tuberculosis (M.tb) could
facilitate the detection of such correlate(s). Here we propose a novel in vivo Bacille Calmette-Gue ´rin (BCG) challenge model
using BCG immunization as a surrogate for M.tb infection. Culture and quantitative PCR methods have been developed to
quantify BCG in the skin, using the mouse ear as a surrogate for human skin. Candidate TB vaccines have been evaluated for
their ability to protect against a BCG skin challenge, using this model, and the results indicate that protection against a BCG
skin challenge is predictive of BCG vaccine efficacy against aerosol M.tb challenge. Translation of these findings to a human
BCG challenge model could enable more rapid assessment and down selection of candidate TB vaccines and ultimately the
identification of an immune correlate of protection.
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Introduction
The ethical barriers to challenging humans with virulent
replicating mycobacteria have so far negated the development of
a human challenge model of M.tb infection. This is in contrast to
infectious diseases such as malaria, influenza and typhoid, where
vaccine developers benefit from the ability to experimentally infect
volunteers to assess candidate vaccine efficacy in small scale proof-
of-concept Phase II challenge studies prior to expensive field
studies [1,2,3,4]. Consequently, the TB vaccine field has to rely on
preclinical animal challenge models of M.tb infection or on the
development of in vitro models of M.tb killing as surrogate measures
of vaccine efficacy [5]. However, it remains uncertain how
predictive these are (if at all) of human vaccine efficacy, and the
development of a relevant in vivo challenge model is urgently
required. Such a model has real potential to facilitate TB vaccine
development. Here we demonstrate a novel in vivo BCG challenge
model using BCG vaccination as a surrogate for M.tb infection.
This is based on the hypothesis that an effective vaccine against
M.tb should also reduce the replication of BCG. Published studies
support this hypothesis: vaccine suppression of a BCG challenge is
comparable to that of an M.tb challenge, and studies have most
commonly assessed the protective effect of the BCG vaccine itself
on a subsequent BCG challenge [6,7,8,9]. Importantly, BCG is
also a feasible challenge agent for human use: it is a safe replicating
mycobacterium (with 99.95% sequence homology to live M. bovis)
[10]. It causes a self-contained limited infection in immunocom-
petent animals and humans, and is licensed for human use as an
intradermal (id) administered vaccine.
While there are clear genetic differences between BCG and
M.tb, the cell-mediated immune responses elicited by both
mycobacteria are very similar. Both organisms are intracellular
pathogens controlled predominantly by CD4
+ T cells, at least in
the early stages of infection. Macrophages infected with both
organisms attract CD4
+ and CD8
+ T cells by MHC class II [11]
and MHC class I presentation respectively, and transfer of
mycobacterial antigens to dendritic cells (DCs) leads to NK cell
activation. IL-17 production from gamma-delta (cd) T cells and
other non-CD4/8
+ cells is also common to both pathogens, and
has been shown to contribute to granuloma formation in lung
tissues in the mouse model [12,13]. Both pathogens have also been
shown to induce Tregs in vivo [14].
The protection against pulmonary TB afforded by BCG is both
variable and incomplete; however, BCG does confer worthwhile
protection against disseminated forms of TB [11]. BCG-based
regimes, designed to improve the efficacy of BCG either by follow-
on with a subunit vaccine boost, or by over-expression of genes
within a recombinant BCG, are currently in the forefront of vaccine
development. We have tested largely BCG-based regimens (BCG
+/2 subunitboost)usingthis challengemodel,althoughapplication
of the model to testing of single dose subunit vaccines and other
non-BCG based regimens is feasible (providing the candidate
vaccine incorporates an antigen that is also present within BCG).
There are few published data on BCG replication in murine
skin, and none beyond two weeks after immunization [15]. Here
we have assessed for the first time the replication kinetics over a
12 week period of a murine BCG challenge administered into the
skin, using the mouse ear as a surrogate for human skin. We have
demonstrated the kinetics of BCG replication with three different
doses of BCG and characterized the associated cellular immune
response to BCG. The aim was to determine the time of the peak
BCG mycobacterial load and use this time-point in subsequent
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candidate TB vaccines on a BCG skin challenge. By identifying
the peak time-point for organ harvest and quantitation of the BCG
mycobacterial load, the ability to detect a significant reduction in
this BCG skin load would be maximised. A proof of concept in the
mouse model was thus established to examine the protective effect
of BCG and candidate TB prime-boost vaccination strategies
against a subsequent BCG skin challenge.
Our results demonstrate that live BCG persists in murine skin
for at least 4 weeks and that id BCG immunization consistently
protects against a BCG skin challenge, an effect that is
independent of immunization dose, route or immunization-
challenge interval. Where BCG-based immunization regimens
are shown to protect, the reduction in BCG CFU counts in the
skin correlates with the pre-challenge CD4
+ T cell responses to
purified protein derivative (PPD) and antigen 85A (Ag85A) in the
blood. Moreover, efficacy of BCG immunization against subse-
quent id BCG challenge is predictive of vaccine efficacy against
aerosol M.tb challenge, suggesting this model may be useful in
predicting vaccine effects against M.tb.
Results
BCG replicates for 4 weeks in the ear and up to 12 weeks
in the local draining LNs
A time-course experiment, measuring out to 12 weeks post
vaccination, described the replication kinetics of BCG in the ears,
local draining (auricular) LNs and spleen following id BCG
immunization. Three different doses of BCG were used: 7000, 60
and 1 CFU. The culture data for the high dose (7000 CFU) and
mid dose (60 CFU) groups are shown (Fig. 1a and 1b). Live BCG
CFU persisted for 4 weeks, after which there was a significant
decline in CFU counts (P=0.04). Animals vaccinated with the mid
dose (60 CFU) showed significantly diminished levels of BCG
throughout the time-course, the levels falling to almost zero after
week 4. No CFU were detected at any time-point in animals
vaccinated with just 1 CFU of BCG (data not shown). The PCR
data are shown for ear CFU in the high dose group (Fig. 1f) and
show a comparable kinetic to culture (1e), with a significant
reduction in CFU between day 0 and week 6 (P=0.03) and again
between weeks 6 and 8 (P=0.009). There was a strong positive
correlation between the levels of BCG estimated by the two
quantification methods across both high and mid doses (R=0.77,
P,0.0001, Spearman).
In contrast to replication in the skin, replication in the LNs was
greater in the mid dose group (Fig. 1d) and followed a similar
kinetic to the high dose group (Fig. 1c). In the high dose group,
peak replication was reached by week 3 and maintained until 8
weeks. There was then a significant decline between week 8 and 12
(P=0.009). In the mid dose group, the peak was delayed (6 weeks),
but was also maintained until 8 weeks, significantly dropping
thereafter (P=0.005).
In summary, live BCG persists in the skin for at least 4 weeks
and in the LNs for up to 12 weeks. These results provided a 4-week
detection window within which candidate vaccines could be
assessed for their ability to protect against a BCG skin challenge.
Immunogenicity of BCG in the spleen is dose-dependent
There are few published data on the immunogenicity of
id-administered BCG in the mouse model, and fewer assessing
the effect of vaccine dose on immunogenicity. The interferon-
gamma (IFN-c) ELISpot responses to PPD over time in the three
groups of animals described are shown in Fig. 2. The high
(7000 CFU) and mid (60 CFU) dose groups showed an increase in
immune response over time, although the kinetic was delayed in
the mid dose group. By week 8, similar levels of IFN-c responses
were observed in both groups (median of 566 spot-forming cells
(sfc) per million splenocytes (mid) vs 788 sfc (high)). In the high
dose group, the ELISpot responses then continued to increase at
the latest (week 12) time-point (median 1298 sfc), whereas in the
mid dose group, the responses reached a plateau (median 496 sfc).
Even the low dose group (receiving just 1 CFU of BCG) showed a
detectable PPD response up to the week 6 time-point, although the
response was not maintained beyond this (Fig. 2c). However, one
animal demonstrated a persistent IFN-c response out to week 12.
ELISpot responses to the immunodominant BCG antigen TB10.3
mirrored the responses to PPD (data not shown).
Single dose subunits, MVA85A and Ad85A, fail to protect
against an id BCG challenge, but BCG immunization
protects against subsequent BCG challenge
Having defined a 4-week window for detection of live BCG in
the skin, we next assessed the ability of candidate vaccines to
protect against an id BCG challenge.
Mice were immunized id with a viral vectored candidate TB
vaccine (MVA85A-Modified vaccina virus Ankara expressing
mycobacterial antigen 85A [16]-or Ad85A-recombinant E1/E3-
deleted adenovirus human serotype 5, AdHu5, expressing antigen
85A [17]), and then challenged four weeks later with BCG. The
amount of BCG in the ears of mice four weeks after BCG
challenge was then quantified (Fig. 3a). There was a trend for a
reduction in CFU counts between naı ¨ve animals and those
vaccinated with MVA85A and Ad85A, but this did not reach
statistical significance (P=0.11 and P=0.16, respectively). Intra-
cellular cytokine staining (ICS) of the local draining LNs showed
that the CD8
+ T cell response to antigen 85A (% of IFN-c-
secreting CD8
+ T cells) was higher for the Ad85A group than
MVA85A or naı ¨ve groups (Ad85A vs naı ¨ve, P=0.02; Ad85A vs
MVA85A, P=0.035). The 85A-specific CD4
+ T cell responses
were similar across both MVA85A/Ad85A groups (Fig. 3b). There
was a strong positive correlation between the lymph node ICS and
spleen ELISpot responses to 85A (R=0.86, P=0.01, Spearman,
data not shown). However, there was no correlation between these
LN/spleen ex-vivo responses and BCG CFU measured in the ear
post challenge (data not shown).
The effect of BCG immunization on subsequent id BCG
challenge was subsequently assessed in a separate experiment (Fig 3
C&D). A significant reduction in BCG CFU was seen in the group
with prior BCG immunization (Fig. 3c) (1.8 logs, P=0.006). A
similar reduction in CFU was also seen in the local draining LNs
(3.2 logs, P=0.0002) (Fig. 3d). Unimmunized control mice,
challenged with BCG and then treated with isoniazid and
rifampicin (I+R) for four weeks, had a comparable level of BCG
CFU to the BCG vaccinated mice. MVA85A, again administered
as a single dose regimen, conferred a non-significant reduction in
BCG CFU, in agreement with the previous experiment (Fig. 3a).
Residual CFU from the first BCG immunization, shown as the
‘‘BCG control’’ group, did not significantly affect the final CFU
result as these CFU counts were negligible (median CFU,10).
BCG protection against a BCG challenge is dose-
independent
We next investigated whether the protective effect of BCG
immunization was dose dependent. A comparable reduction in the
CFU count of challenge was seen when a 1-log reduced BCG
immunization dose of 2.5610
3 CFU was administered
(P=0.0005, Fig. 4a). The challenge dose administered was the
BCG Challenge Model in Mice
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reduction in the LN CFU counts (P=0.0005, Fig. 4b).
BCG immunization protects against BCG challenge at a
distant site
In the model being developed, an id BCG challenge is being used
as a surrogate for aerosol M.tb challenge. As route of challenge may
be important, we next compared the efficacy of id BCG vaccination
on both id and in BCG challenge in parallel (Fig. 4c). Prior id BCG
immunization resulted in a significant reduction in lung CFU (1.3
logs) after an in challenge (P=0.002), which was comparable to,
though of lesser magnitude than the reduction seen in the skin after
an id challenge (1.8 logs, Fig. 4a). When the BCGimmunization was
administered in (Fig. 4d), a 2.4-log reduction in BCG CFU in the
lung was observed. This suggests that a greater reductioninCFU by
BCG may be achieved when immunization and challenge are
administered to the same site.
Effect of BCG immunization on subsequent BCG
challenge is durable
We assessed the durability of protective efficacy by evaluating a
16-week window between BCG immunization and subsequent
challenge. Mice were immunized id with BCG and then
challenged with BCG 16 weeks later, with or without an inter-
vening period of antibiotic therapy (Fig. 5a, timeline). There was a
significant reduction in CFU (1 log) in the ears of BCG-immunized
Figure 1. Timescale showing BCG persistence in the ears and LNs of id-injected mice up to 12 weeks post immunization. Log BCG CFU
in the ears (estimated by culture) are shown for (a) the high dose group (7000 CFU id); and (b) the low dose group (60 CFU id). Log BCG CFU in the
auricular LNs are shown in (c) the high dose group (7000 CFU id); and (d) the mid dose group (60 CFU id). Datasets include individual data points for
each mouse; the bars represent the median per group in (a) and (b), and a line connects the means for each group in (c) and (d). * indicates P,0.05.
Both ears and LNs were homogenized and plated onto 7H11 Middlebrook agar. Log BCG CFU in the ears estimated by culture (e) and BCG genome
copies/mHPRT copies estimated by PCR (f) are shown in a timescale for the high dose group, up to 12 weeks post BCG immunization. Quantitative
PCR was performed with BCG-specific primers. Individual data points are shown for each mouse with a line connecting the means for each group.
doi:10.1371/journal.pone.0019840.g001
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Fig. 5c). A similar reduction in CFU (0.75 log) was seen in the local
draining LNs (Naı ¨ve:BCG, P=0.004; Fig. 5d).
Fig. 5b shows the post-challenge ELISpot responses of the same
animals (20 weeks post initial BCG immunization in the id
immunized group). Here the BCG-immunized group (BCG, group
2) demonstrated significantly increased post-challenge responses to
PPD, compared to the naı ¨ve (challenge-only) group 1 (P=0.001).
These results suggest that the protective effect of BCG
immunization on BCG challenge is not only dose-independent,
but also independent of the immunization-challenge interval
(at the intervals measured: 4 and 16 weeks).
Antibiotic clearance of live replicating BCG does not
reduce vaccine efficacy
Two additional groups were included in the previous experi-
ment to assess the effect of antibiotic clearance of the BCG vaccine
on a subsequent id BCG challenge (groups 3 and 4, see timeline,
Fig. 5a). Data from group 3 (BCG+(I+R)+(no challenge)), showed
the effect of delayed antibiotic treatment on the immune response
from the prior BCG immunization. Immune responses to PPD
between this group and group 2 (who received no antibiotics after
BCG immunization and also went on to receive a challenge) were
comparable. In addition, there were significantly higher PPD
responses in these groups compared to the naı ¨ve (challenge-only,
group 1) animals (P=0.005). Again, efficacy was maintained in the
group receiving antibiotics (4): Naı ¨ve: BCG, P=0.005, Naı ¨ve:
BCG+(I+R), P=0.01.
These results demonstrate that the administration of antibiotic
therapy 8 weeks post BCG immunization is sufficient to kill all
remaining viable bacteria, but does not attenuate the immune-
mediated efficacy of the priming BCG immunization.
Efficacy in the skin produced by BCG and BCG-MVA85A/
Ad85A regimes correlates with PPD and Ag85A-specific
pre-challenge CD4
+ T cell responses in the blood
The hypothesis that the protective effect of BCG could be
boosted by a candidate subunit vaccine was subsequently tested
using this challenge model. The effect of prime-boost regimes
BCGid-MVA85Aid (B–M) and BCGid-Ad85Aid (B-Ad) on BCG
challenge, in comparison to BCG alone (BCG), is shown in Fig. 6.
All three regimes achieved comparable reduction in BCG CFU
counts in the skin and LNs. (Fig. 6c: Ear CFU: BCG, (P=0.0004),
B–M, (P=0.0014) and B-Ad, (P=0.0008); LN CFU: BCG,
(P=0.001), B–M, (P=0.0008, P=0.001).
T cell responses were assessed in the blood by ELISpot pre-
BCG challenge to allow the potential for identification of a pre-
challenge immune correlate. The PPD response to BCG was
significantly boosted by MVA85A (P=0.001) but not by Ad85A
(P=0.29 Fig. 6b). The response to a H-2
d CD4
+ T cell epitope
from antigen 85A induced by BCG was significantly boosted by
both MVA85A (P=0.0008) and Ad85A (P=0.006), but was
Figure 2. Splenic IFN-c responses to PPD up to 12 weeks post BCG immunization. In (a) high dose group (7000 CFU id); (b) mid dose group
(60 CFU id) and (c) low dose group (1 CFU id). Datasets include individual data points for each mouse; the bars represent the median value per group.
Results expressed as SFC/million splenocytes.
doi:10.1371/journal.pone.0019840.g002
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(P=0.002). Similarly, the response to a H-2
d CD8
+ T cell epitope
from antigen 85A was boosted by both subunits; Ad85A (P=0.0008),
MVA85A (P=0.001), but was significantly higher in the B-Ad
compared to B–M group (P=0 . 0 0 0 8 ) .T h i si si na g r e e m e n tw i t ht h e
known predilection of these subunit candidates for a predominantly
CD4
+ (MVA) or CD8
+ (Ad) biased T cell response. There was a
significant negative correlation between the pre-challenge PPD
response and the level of challenge BCG CFU in the draining LNs,
in immunization groups BCG, B–M and B-Ad (R=20.81,
P,0.0001, Fig. 6e). There was a weak negative correlation between
the pre-challenge CD4 response to the CD4 epitope and challenge
CFU (R =20.42, P=0.04, Fig. 6f). No significant correlation was
observed between the pre-challenge responseto the CD8 epitope and
challenge CFU (R=0.54, P=0.14,Fig.6g).
In summary, subunit booster vaccines MVA85A and Ad85A
failed to significantly augment the protective effect of BCG alone
(at the challenge dose assessed). However, efficacy in the skin
produced by both BCG alone and BCG-MVA85A/Ad85A
regimes correlated with the pre-challenge CD4
+ T cell responses
to PPD and Ag85A.
Discussion
We have presented a novel in vivo challenge model for testing
candidate TB vaccines. This model was developed as a preclinical
model of a human challenge model, and the data and techniques
presented in this manuscript formed the basis of a clinical study
which successfully translated this approach into the human setting
(Minassian et al., submitted).
We demonstrate the persistence of BCG in the skin for up to
four weeks at a level that allows for suppression by a protective
vaccine regimen, and our model suggests that protection against a
BCG skin challenge (by prior BCG-based immunization) is
Figure 3. Effect of single dose vaccines (subunits MVA85A and Ad85A, and BCG) on an id BCG challenge. (a) BALB/c mice were
immunized id with 1610
6 pfu MVA85A or 2610
9 vp Ad85A. Control mice (Naı ¨ve) received no immunization. Four weeks later all mice were
challenged id with 1610
5 CFU BCG, contralaterally to the site of vaccination. Ears and LNs were harvested 4 weeks after BCG challenge and processed
for CFU quantification. (*P,0.05, n=10 except naı ¨ves, n=5). (b) Corresponding intracellular cytokine staining (ICS) of the local draining LNs. Red bars
represent the proportion of IFN-c-secreting CD4
+ T cells in response to 85A, blue bars represent the same for CD8
+ T cells (M, n=4; Naı ¨ve, n=3; Ad,
n=4. *P,0.05). (c) Effect of BCG vaccine compared to subunit MVA85A on an id BCG challenge. BALB/c mice were immunized id with either
1610
6 pfu MVA85A or 2.2610
4 cfu BCG. ‘‘Naı ¨ve’’ and antibiotic-treated (I+R) mice received no immunization. Four weeks later all mice were
challenged with 6610
3 CFU BCG, except the BCG control group who received no challenge. In the I+R group, challenge was followed by 4 weeks
treatment with isoniazid and rifampicin. Ears and LNs were harvested 4 weeks after BCG challenge and processed for CFU quantification. Log10 BCG
CFU individual data points for each mouse are shown. Bars represent the median per group. (c) Ears (**P,0.01, ‘‘non-significant, ND’’, n=10); (d) LNs
(**P,0.01, ‘‘non-significant, ND’’, n=10).
doi:10.1371/journal.pone.0019840.g003
BCG Challenge Model in Mice
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supports the development of a mycobacterial skin challenge as a
model for M.tb exposure and challenge.
Our results show for the first time that live BCG persists in the
skin for at least four weeks, and in the lymph nodes for up to
12 weeks, the latter coinciding with the peak splenic T cell
immune response. Whether detection of live BCG at the vaccine
site can be taken as evidence of true in-situ replication is an
important question. The natural course of BCG replication in the
spleens of iv-vaccinated mice is a 0.5-1-log increase in CFU in the
first 10–14 days. However, the peak CFU level reached is
comparable to the dose initially administered, with no significant
increase beyond this. Similarly, in the lungs of iv vaccinated mice,
there is a 3-log increase in BCG replication over the first 4 week
period, but again the peak CFU level reached is comparable to the
dose administered [6]. We found no significant rise in CFU in the
mouse ear after day 0 with no true detectable peak, but similar to
the previous published work, the numbers of live BCG detectable
in the first 4 weeks are not different from the levels seen at day 0.
There is likely to be a balance in the level of bacterial replication
and clearance during this period-the clearance being attributable
to either bacterial death and phagocytic clearance, or phagocytic
transport of live bacteria to the local draining LNs. This may in
part explain the different kinetics in the LNs, where there is likely
to be a greater proportion of live bacteria and so where BCG
replicates to much greater levels, compared to the ear where there
are relatively few lymphoid cells and where phagocytic clearance
may have a prominent role. Recent work has demonstrated the
use of an endogenous bacterial enzyme probe in rapid detection,
imaging and quantification of M.tb and BCG within tissues of a
living host. This could potentially play a role in quantifying BCG/
M.tb challenge over time in vivo and ultimately may provide an
alternative method for quantifying mycobacteria in mice [18].
This model uses BCG administered id as a surrogate for
challenging with M.tb by aerosol. We therefore evaluated how
predictive the protective effects seen in the BCG id (skin) challenge
model are of those seen in the aerosol (lung) challenge model, by
investigating the effect of BCG on both id and in BCG challenge in
parallel. We have demonstrated that suppression of a BCG skin
challenge canbe achievedby priorBCGimmunization,consistently
Figure 4. Effect of BCG on a 4-week id and in BCG challenge. BALB/c mice were immunized id with 2.5610
3 CFU BCG. Naı ¨ve and antibiotic-
treated (I+R) mice received no immunization. Four weeks later all mice were challenged either id or in with 4610
3 CFU BCG, except the BCG control
group who received no challenge. Immediately post-challenge the I+R group was treated for 4 weeks with isoniazid and rifampicin. Ears (a), LNs (b)
and lungs (c) were harvested 4 weeks after challenge (spleen cfu data not shown). (d) shows the effect of in BCG on in challenge in a separate
experiment. Here, BALB/c mice were immunized in with 1610
3 CFU BCG. Naı ¨ve mice received no immunization. 4 weeks later in-immunized and
naı ¨ve mice were challenged with 4610
4 CFU BCG in. The ‘‘BCG in control’’ group received no challenge. Lungs were harvested 4 weeks after BCG
challenge in all groups. CFU from plating of fresh tissues are shown. Log10 BCG CFU individual data points for each mouse are shown. Bars represent
the median per group. (a) Ears (**P,0.01, n=10); (b) LNs (**P,0.01, n=10); (c) Lungs (**P,0.01, n=10); (d) Lungs P,0.01, n=8 naı ¨ve; n=6 BCG in;
n=8 BCG in control).
doi:10.1371/journal.pone.0019840.g004
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the local draining LNs, and is similar to the magnitude of
suppression that id BCG exerts on a distant lung challenge. This
protective effect (of BCG id on BCG id challenge and of BCG id on
BCG in challenge) also mirrors the effect of parenteral BCG on M.tb
aerosol challenge in previous published studies [7,19,20,21]. This
latter finding suggests that if a BCG-based vaccine regimen is
protective against M.tb, its effect on suppression of a BCG skin
challenge may predict its effect on an aerosol challenge.
Our experiments have shown the protective effect of BCG to be
independent of the route or dose of BCG administered, and also of
the immunization-challenge interval. Longer interval experiments
should be performed to better test the protective effect of BCG-
induced central and effector memory T cell responses. Olsen et al.
demonstrated that immunity measured in the spleen declined in
BCG-immunized mice when the microorganisms were cleared by
antibiotic therapy, compared to non-antibiotic-treated animals,
where immune responses were maintained until 9 months [22].
While we have shown the immunogenicity not to be affected by
antibiotics (in spite of successful eradication of all live BCG), we
have only measured this at one time-point post BCG immuniza-
tion (20 weeks). There were additional differences between ours
and Olsen’s experiments: Olsen et al. cleared BCG with antibiotics
at 15 weeks post-immunization and continued the antibiotics for
8 weeks, whereas in our model antibiotics were started 8 weeks
post-immunization and continued for 6 weeks. Our mice were also
vaccinated by the id as opposed to sc route. However, in agreement
with Olsen’s data, we show that antibiotic clearance of live
replicating BCG post-immunization does not ablate efficacy
against a subsequent mycobacterial challenge (as measured by
Figure 5. Effect of BCG immunization on a 16-week id BCG challenge. Timeline is shown in (a). BALB/c mice were immunized id with
1610
4 CFU BCG. Naı ¨ve mice received no immunization. 16 weeks later all mice were challenged with 10
3 CFU BCG, except the (BCG+(I+R)
(no challenge)) group. This group and the BCG+(I+R) group received 6 weeks of isoniazid and rifampicin (starting 8 weeks post initial BCG
immunization). In the BCG+(I+R) group, there was a 2 week wash-out period between cessation of antibiotics and subsequent BCG challenge.
(b) shows the splenic IFN-c ELISpot responses to PPD and TB10.3, in naı ¨ve, BCG-vaccinated, and BCG+(I+R)(no challenge) animals, 4 weeks post BCG
challenge. Whiskers represent minimum to maximum values, boxes the interquartile range, and the bars the median values for each group (*P,0.05,
**P,0.01, ‘‘non-significant’’, ND. n=10, except for BCG+(I+R); n=2). Ears and LNs were harvested 4 weeks after BCG challenge and processed for CFU
quantification. Log10 BCG CFU of challenge are shown, for groups 1 (Naı ¨ve), 2 (BCG) and 3 (BCG+(I+R)). For group 4 (BCG+(I+R) no challenge), the ear
and LN CFU correspond to the CFU remaining from the priming BCG immunization (zero in all animals). Individual data points for each mouse are
shown. Bars represent the median per group. (c) Ears (*P,0.05,**P,0.01, n=10); (d) LNs (**P,0.01, n=10).
doi:10.1371/journal.pone.0019840.g005
BCG Challenge Model in Mice
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challenge CFU in the lung (Olsen et al.)) This suggests that once
generated, protective immunity to BCG is maintained, even in the
absence of replicating live mycobacteria. It will be important to
determine the minimum time window required for immune
engagement by BCG and development of protective immunity.
Our prime-boost immunogenicity data indicate a correlation
between pre-challenge PPD/Ag85A-specific CD4
+ T cell respons-
es in the blood and efficacy (reduction in BCG CFU counts) in the
skin. However, the phenotype of such ‘‘protective’’ CD4
+ T cell
responses has yet to be fully defined. Multiple gene knockout (KO)
studies, cell depletion and adoptive transfer experiments in mice
demonstrate the importance of CD4
+ T cells in protective
immunity against TB [23,24,25,26,27,28,29,30]. However, the
precise mechanism of CD4
+ T cells in protection against
mycobacterial challenge remains to be defined.
While the dose of BCG does not affect its protective capacity,
we have shown that it does affect the peak organ bacterial load, in
agreement with other published studies [31,32,33,34]. Challenge
dose is important, as efficacy of any immunization regimen may be
affected by dose. This was demonstrated by our prime-boost
experiment of BCG-MVA85A and BCG-Ad85A on BCG
challenge. Here, improvement over the suppressive effect of
BCG alone by these id-administered subunits was not achievable
at a challenge dose of 10
3–10
4 CFU, in these relatively small
numbers of animals, as the protective effect of BCG is so profound.
This is in agreement with published data on the effect of
parenterally-administered BCG-MVA85A/Ad85A compared to
Figure 6. Effect of BCG, BCG-MVA85A (B–M), and BCG-Ad85A (B-Ad) prime-boost regimes on an id BCG challenge. Timeline shown in
(a): BALB/c mice were immunized with 10
4 CFU BCG id and then boosted after 13 weeks with either 1610
6 pfu MVA85A id or 2610
9 vp Ad85A id. All
animals were challenged 4 weeks later with 6610
3 CFU of BCG id. Organs were harvested 4 weeks after challenge. Log10 BCG CFU of challenge are
shown in (c) Ears (***P,0.001, **P,0.01, n=8); and (d) LNs (***P,0.001, **P,0.01, n=8, ‘‘NS’’=no significant difference). **/*** indicate significance
of immunization regimes over naı ¨ve mice. (b) Pre-challenge immunogenicity as measured in the blood by ELISpot. IFN-c responses were
assessed after stimulation with PPD, a H-2
d CD4
+ T cell epitope, and a H-2
d CD8
+ T cell epitope present in the M.tb antigen 85A, on blood samples
taken one day pre- BCG challenge. IFN-c responses within all three vaccinated groups (BCG (B), BCG-MVA85A (B-M), and BCG-Ad85A, (B-Ad), n=10)
are shown. Whiskers represent minimum to maximum values, boxes the interquartile range, and bars the median values for each group. Correlations
between LN cfu and pre-challenge blood ELISpot responses to (e) PPD; (f) CD4
+ epitope; and (g) CD8
+ epitope. Spearman correlation analysis (with
individual data-points for all 30 mice in the three vaccination groups) is shown.
doi:10.1371/journal.pone.0019840.g006
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These data therefore support this skin model in its prediction of
BCG-based vaccine effects against lung challenge with M.tb.A
non-significant effect on BCG id challenge also mirrored the lack
of effect on M.tb aerosol challenge (seen in previous studies) for the
single dose subunit regimes tested, e.g., single dose parenterally-
administered Ad85A [36,37].
The convincing effect of BCG against BCG challenge in this
murine model has been validated against the extensive literature
on the effect of BCG against M.tb challenge in mice. This finding is
very relevant for many mycobacteria-based vaccine regimens
currently in development (including recombinant strains of BCG
and attenuated strains of M.tb).
Given the purpose of this study is to support the development of
a human challenge model, further assessment of protective non-
BCG-based candidate subunit vaccine regimens (which do not
replicate /disseminate like BCG and may protect via different
mechanisms of action) may be more feasible in humans and more
relevant non-human primate pre-clinical models. In these models,
the known variable effect of BCG should allow more scope for
improvement in protection by a candidate subunit vaccine or
BCG booster regimen, compared to the mouse model where the
effect of BCG is consistently profound.
The relationship between protective immunity in the skin to
that in the lung remains to be fully ascertained. However,
comparisons of the effect of id BCG vaccination against id and in
BCG challenge in this work support a predictive relationship
between efficacy against id BCG and aerosol M.tb. While
comparative parallel studies of the effects of new candidate
vaccines against challenge with BCG id and M.tb aerosol, would
validate this id model in prediction of effects against aerosol M.tb
challenge, there is extensive published work by several groups over
the last few decades showing that the data against BCG challenge
in this paper (with BCG) accords with the effects of BCG against
M.tb challenge.
In summary, we have assessed the ability of candidate vaccines
to protect against a BCG skin challenge in mice, and BCG itself
has been shown to consistently protect. This mirrors published
data of the effects of BCG on M.tb challenge, supporting the
relevance of a mycobacterial skin challenge to an aerosol M.tb
challenge for assessment of BCG-based vaccines. These findings
are now being applied to a human model of BCG challenge,
where replication of BCG in human skin has been characterized
and its replication within an immunized group of volunteers is
being assessed (Minassian et al., manuscript submitted). A
challenge model such as this which allows vaccine assessment
could be enormously valuable in candidate TB vaccine down
selection, and better still if an immunological profile associated
with reduced BCG bacterial load in the skin could be identified.
Materials and Methods
Animals and Immunizations
All procedures were carried out under the terms of the UK Ani-
mals (Scientific Procedures) Act Home Office Project Licence (UK
Home Office PPL 30/2412) and were approved by the University
of Oxford Animal Care and Ethical Review Committee.
The studies described used 6–8 week old female BALB/c (H-2
d)
(Harlan, UK). Animals were vaccinated with one or more of BCG,
recombinant MVA85A, or recombinant Ad85A. 25–30 mlo f
vaccine was inoculated into the ear dorsum. Animals were then
challenged with BCG id into the contralateral ear. All intranasal
exposures were performed in a class I hood. Mice were removed
and immunized with 50 ml given drop-wise to the nares.
The doses of each vaccine used, unless otherwise stated, were
10
1–10
5 CFU of BCG, 10
6 plaque-forming units (pfu) recombi-
nant MVA85A or 2610
9 viral particles (vp) Adeno(AdHu5)85A
[38]. Viable freeze-dried BCG vaccine SSI (Danish strain 1331)
was used for all experiments.
Tissue harvest and homogenization
Mice were sacrificed by cervical dislocation and tissues
(lungs, spleens, ears, lymph nodes (LNs)) removed by dissection
in a sterile fashion and homogenized. Lungs, LNs and spleens
were beaten in a mini-bead beater (Glen Mills inc) for 1 min in
2 ml V-bottom cryovials (Starstedt) containing 1/3 glass beads
and 1 ml Dulbecco’s phosphate-buffered saline (DPBS). Dilu-
tions of tissue homogenates were then made 10-fold in PBS
(900 mlP B S ,1 0 0 ml tissue); 1 dilution for spleens and 2
dilutions for ears, LNs and lungs. 100 ml of each neat sample
and each dilution were plated onto 7H11 agar containing 10%
OADC supplement (E&O laboratories). Plates were incubated
at 37uC for 3–4 wk and the number of BCG colonies (CFU)
counted.
Ears were homogenized in a dispomix machine (Thistle
Scientific) after transfer into dispomix tubes containing 1 ml of
sterile PBS. A 2-step program was applied: Program 5– involving a
20 s gradation spin/cut cycle; Program 11– involving 90 s of
homogenization (fibrous tissue specific). The homogenate was then
sonicated at half power for 15 s.
DNA extraction of BCG from tissue
200 ml of a 1 ml tissue homogenate (mouse ear or human skin)
in DPBS was beaten for 4 min in a mini bead-beater (Glen Mills
Inc), until smooth. 180 ml of ATL (tissue lysis) buffer and 20 ml
proteinase K (PK, Qiagen) were added, vortexed and the sample
incubated at 56uC in a shaking heating block for 4 h. The sample
was then heated to 95uC for 15 min to inactivate the PK. Once
cooled, chicken egg-white lysozyme (Sigma), (final concentration
0.5 mg/ml), was added and the sample incubated for 1 h at 37uC.
After vortexing for 15 s, 400 ml AL buffer & 400 ml 100% ethanol
(premixed) were added to the sample and vortexed. From this
point, Qiagen manufacturer’s instructions were followed. The
DNA was eluted with AE buffer (200 ml). After incubation for
1 min at room temperature, the column was centrifuged at
8000 rpm for 1 min. The elution was then repeated with a further
200 ml of AE buffer to maximize DNA yield, making the final
sample volume of DNA 400 ml. The sample was frozen
immediately at 220uC.
Primers
C3/5 primers, designed by Magdalena et al [39], are specific
for the senX3-regX3 region, an intergenic region (IR)
separating two genes encoding a mycobacterial two-component
system. Depending on the BCG substrains examined, BCG
Danish has been shown to give a product of 276-base pairs (bp),
whereas strains of M. bovis and M.tb give a larger product of
329+ bp.
ET 1 and 3 are complementary to regions flanking the BCG
deletion RD1 sequence. In strains without RD1 (all strains of
BCG) they bind and amplify a 196-bp region, but in strains
with RD1, the 9650-bp sequence is too big to efficiently amplify
[40].
Using primer design software the published sequences were
modified to minimize the risk of self-binding and primer dimer
formation. Table 1 shows the final sequences of these BCG-
specific primers (showing base pair differences from the original
published sequences underlined).
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5 ml of each DNA sample (neat, 1:10 or 1:100 dilutions) was
added to wells in a 96-well plate, each well containing a mixture of
10 ml of SyBr Green mastermix (Sigma), 3 ml of RNAase-free
water (Sigma) and 2 ml of a 10 pmol/ ml mix of both forward and
reverse primers (MWG biotech), giving a final reaction volume per
well of 20 ml. A 15 min denaturation step (at 95uC) was followed
by 50 cycles of amplification, including an annealing step at 60uC
for 30 s and an extension step at 72uC for 30 s, followed by melt
and cooling programs. To control for variation in DNA quantity
between samples the copy number of the gene of interest was
divided by the copy number of the house keeping gene mHPRT.
All PCR reactions were performed in duplicate.
A standard curve was made by extracting BCG DNA from
serial 1 in 10 dilutions of BCG. Five fresh vials (each containing
,1610
6 CFU) were together reconstituted in 1 ml PBS. Serial 1
in 10 dilutions were made from this starting stock (100 ml into
900 ml PBS), from ,5610
6-.5610
22/ml. DNA was extracted
from 200 ml of each 1 ml dilution, culminating in final volume of
DNA of 400 ml. 5 ml of each 400 ml DNA sample was subsequently
used for each PCR reaction. Therefore 5 ml of DNA represented a
range from ,1.25610
4–1.25610
24 CFU per PCR reaction
(5 ml680=400 ml DNA; 400 ml DNA=200 ml BCG;
200 ml65=1 ml BCG). Both primer sets produced a linear result,
confirming the PCR was efficient, from 1.25610
3–
1.25610
22 CFU. The standard curve was subsequently corrected
for live CFU, by solid culture CFU quantification of the same
BCG aliquots. There was .0.5 log discrepancy in CFU between
the culture results and the estimated number of BCG genome
copies by PCR. The standard curve was therefore adjusted, such
that 1.25610
1 estimated copies corrected to 2.32610
0 live copies
of BCG. The PCR limits of CFU detection in a 1 ml tissue
homogenate therefore ranged from a minimum of ,0.9 BCG
CFU/ml tissue (0.09 CFU from a plated 100 ml aliquot of tissue)
to a maximum of ,9610
4/ml tissue. The lower end of detection
by PCR reflected a 10X increase in sensitivity over culture. While
the maximum concentration of amplifiable BCG was just under
10
5 CFU, this was considered adequate for detection of BCG in
the skin given an average administered dose of 10
3 to 10
5 BCG
CFU.
Antibiotic therapy
Antibiotic preparations of rifampicin (R3501, Sigma) and
isoniazid (I3377, Sigma), were added to 400 ml drinking water
bottles, to make a final concentration of each antibiotic in water of
100 mg/l. The bottles were then administered to the animals’
cages in the usual procedure. This dual therapy was administered
to antibiotic control groups of mice for 4 weeks to ensure complete
eradication of BCG.
Cell isolations
Cells from freshly harvested spleens and LNs were resuspended
in 5 ml M10 (Modified Eagle’s Medium alpha-modification
(Sigma), supplemented with 10% heat-inactivated Foetal Calf
Serum (FCS), 2 mM L-glutamine, 1% penicillin/streptomycin and
50 mM 2-mercaptoethanol (Gibco)).
Approximately 100 ml of blood was collected from tail veins into
200 mL of 1 M EDTA. Erythrocytes were lysed using Puregene
RBC Lysis Solution (Flowgen) and peripheral blood mononuclear
cells (PBMCs) harvested by centrifugation at 4000 rpm for 4 min.
The cell pellet was resuspended in 500 ml M10. Cells were counted
using a CASY counter (Scha ¨rfe Systems, Germany) and
resuspended in complete medium.
Mouse ex-vivo IFN-c ELISpot assay
The enzyme-linked immunospot (ELISpot) IFN-c assay was
carried out as previously described [41]. Cells from immunized
and naı ¨ve control mice were resuspended at 5610
6 or 1610
7
cells/ml (splenocytes) or 8610
5 cells/ml (lung cells) in M10.
PBMCs were resuspended at variable concentrations and plated
with 0.5 and 0.25610
6 naı ¨ve splenocytes per well. 50 ml cells were
plated in duplicate into the coated wells, serial 1 in 2 dilutions were
made if necessary. Cells were assayed following 18–20 h of sti-
mulation with Tuberculin PPD (20 mg/ml, SSI), r85A (10 mg/ml,
University of Leiden), and 17 overlapping peptides of TB10.3 and
TB10.4. Cells from 5–10 individual mice were tested in each
group, and each condition was tested in duplicate. All of the
peptides used were 15mers overlapping by 10 amino-acids, used at
a final concentration of 10 mg/ml in each well. Stimulation of
PBMCs was performed with a H-2
d CD4
+ T cell epitope from
antigen 85A (sequence: tfltselpgw lqanrhvkpt), and a H-2
d CD8
+ T
cell epitope (sequence: ewydqsglsv vmpvggqssf).
Phytohaemagluttinin (PMA, 10 mg/ml) was used in all assays as
a positive control and M10 alone as a negative control. Cells were
counted using an ELISpot counter (Autoimmun Diagnostika,
Germany).
The ELISpot data were analysed by subtracting the mean
number of spot-forming cells (sfc) produced from the negative
control wells from the mean count from stimulated wells. A well was
consideredpositiveif the count wasatleasttwicethat inthe negative
control wells and at least 5 spots more than the negative control
wells. Positive control wells were stimulated with PHA and the
control failed if there were not more than 200 spots/well. Results
are expressed as either median spot forming cells (sfc) per million
splenocytes, lung cells or PBMCs, or as median sfc/spleen or lung.
Cell stimulations and antibody staining for flow
cytometric analysis
Cells were adjusted to a concentration of 1–2610
7 cells/ml in
M10 and 100 ml/well were plated into a round bottom 96-well
plate. 50 ml of GolgiPlug (1:250 dilution) (BD Pharmingen) was
added to each well, together with 50 ml/well of antigen 85A pools
at 4 mg/ml final concentration. Plates were incubated at 37uC/
5%CO2 for 5 h and then refrigerated at 4uC.
Cells were transferred to a V-bottom plate and centrifuged for
2 min, 1800 rpm, blocked with 100 ml Fc-c receptor block (anti-
CD16/32) and incubated for 15 min on ice. Cells were
centrifuged at 1800 rpm for 2 min, flicked and vortexed. 50 ml
of surface antibodies diluted in PBS containing 1% FCS (PBS1%)
were added and plates incubated for 15–30 min on ice. After
washing twice in 160 ml PBS1%, 100 ml of Cytofix/cytoperm
(BD Pharmingen) was then added to each well and plates
incubated for 10–20 min at 4uC. 100 ml of Perm/Wash (BD
Table 1. Final sequences of BCG-specific primers, C3/5 and
ET1/3, showing base pair differences from the original
published sequences underlined.
Primer Sequence
C 3/5 (forward) 59 –GAA CTG CGG TCA AAC AGG TCA CAA C -39
C3/5 (reverse) 59 –AGC GAC TCC TCG TCC TCC ACA ATC -39
ET 1/3 (forward) 59 –CCG CCG ACC GAC CTG ACG AC -39
ET 1/3 (reverse) 59 –GGC GAT CTG GCG GTT TGG GG -39
doi:10.1371/journal.pone.0019840.t001
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Plates were washed twice in a further 160 ml of Perm/Wash.
25 ml of intracellular Abs diluted in perm/wash were added to
each well and incubated on ice for 15–30 min. Cells were washed
twice in Perm/wash and resuspended in 150 ml PBS-1% formalin.
Flow cytometric analysis was performed within 48 h of staining,
using a Cyan ADP flow cytometer (BD Biosciences). Data were
analyzed using FloJo (version 9). Responses to unstimulated wells
were used to establish the gates. Data are presented as % of the
total number of cells. This was determined by multiplying the % of
IFN-c
+ CD4
+ or CD8
+ cells of the parent population of CD4
+ or
CD8
+ cells by the total cell count.
Statistical Analysis
Data from all immunological assays and BCG challenge
experiments were not normally distributed. Consequently, results
are presented as medians with interquartile ranges plotted, and
non-parametric tests have been applied. Differences in BCG CFU
between groups have been analyzed using the Kruskall Wallis test
(for comparison of more than two independent groups) and Mann-
Whitney U two-sample statistic tests, for comparison of two
groups. Paired t-tests have been used for within subject
comparisons. Correlations between different parameters were
analysed by computing the Spearman’s rank correlation test,
together with the level of significance. The statistical software used
was STATA (Stata Corporation, Texas).
Differences were considered statistically significant, when
P,0.05. Levels of significance were indicated by asterisk
(*P,0.05, ** P,0.01 and ***P,0.001). Results are stated in
figure legends, unless referred to in the text. All non-parametric
data are shown as median6range. Graphs were generated by
using Prism 5 software (Version 5.01; GraphPad Software Inc.,
CA, USA).
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